The UK may see medicine shortages and delays in the introduction of new medicines after Brexit.

by | Jun 12, 2017 | Brexit, NHS

The EU market accounts for 25% of all global medicines sales, when we break away and become a smaller separate market, companies may very well priorities bigger markets to introduce their medicines into over the UK.  The NHS may as a result struggle to access medicines and combined with the drop, in value of the pound against the euro and the dollar what we can access will cost more.  The NHS is already struggling to work within its budgets and targets this will make things worse. The NHS must be considered in future Brexit negations, or we may see  shortages of medicines in the future.

Testimonials

I attended one of the first virtual GDP Responsible Person Cogent “Gold Standard” training sessions due to the Covid-19 social distancing requirements. regardless of the circumstances the training was well organised and delivered to the required standard. This is why I recommended my associates to utilise PCL. Thank you Ryan, Sally, Adel and Jackie. Goncalo Sousa –  Quality Head UK at the Janssen Pharmaceutical Companies of Johnson & Johnson 05/05/2020
Cogent Gold Standard GDP Online Training